

Rahman et al.

Double-blinded infliximab dose escalation in patients with rheumatoid arthritis  
Annals of the Rheumatic Diseases manuscript #ANNRHEUMDIS/2006/065995

## **Supplemental Materials 2**

### *Antibody Status and Response*

The proportion of responders at the last visit by antibody status is summarized in the figure below. Patients who did not dose escalate or received only 1 dose escalation and were positive for antibodies to infliximab had lower response rates compared with those who were antibody negative or had an inconclusive antibody status. Patients who received 2 or 3 dose escalations and were positive for antibodies to infliximab had similar response rates compared with those who were antibody negative or had an inconclusive antibody status; however, the numbers of patients in these groups were relatively small. With the exception of this group of patients who received all 4 dose escalations, the majority of dose escalating patients who were positive for antibodies to infliximab responded, with response rates ranging from 64.7% (11 of 17 patients) among patients who received 1 dose escalation to 100% (4 of 4 patients) among patients who received 3 dose escalations.

Rahman et al.

Double-blinded infliximab dose escalation in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases manuscript #ANNRHEUMDIS/2006/065995

Figure: Summary of antibody to infliximab status by number of dose escalations for patients in Group 2. Although there were 7 subjects who received 4 dose escalations, none of them responded, and only 1 was antibody positive.

